Do you want to significantly lower your overall cost of goods for industrial-scale manufacturing?
Phenotypeca can help you:
- Reduce overall product development time
- Increase the quality of your final protein
- Reduce regulatory risk
Phenotypeca has the ‘go-to’ platform for the development of baker’s yeast strains for industrial-scale manufacture of vaccines, therapeutics and other recombinant proteins. These markets had over $200 billion in revenue globally in 2020.
We offer an animal-free, sustainable option for these markets as well as other industrial applications.
Our team were involved in developing extensive yeast breeding techniques and genome sequencing in the 1990s. They were also involved in creating and filing the patents for the first-generation baker’s yeast platform. They have developed processes for vaccines, therapeutics, and recombinant proteins such as Recombumin®, which have achieved EU and FDA approval.
“To make medical treatments more affordable for everyone using baker’s yeast”
Dr Chris Finnis
Intellectual Property and Projects Director
PhD in Microbial Genetics from the University of Nottingham, MSc in Biochemical Engineering (UCL), Biotechnology BSc (Hons) from University of Leeds. 30-years industrial experience in yeast strain development for recombinant protein production. Royal Society Entrepreneur-in-Residence and inventor on multiple patents with a passion for bringing new products to the market. When not enjoying yeast-derived products, loves kayaking and the great outdoors.
Professor Ed Louis
Research and Development Director
PhD in Genetics from The University of California at Berkley, BSc in Biology and Mathematics from Clarkson University. Experienced in yeast genetics, genomics, and evolution; was a key part of the yeast genome sequencing project, now developing tools for exploiting its natural genetic/phenotypic variation. Thoroughly enjoys the products of yeast (wine, beer and bread).
MSc Biochemical Engineering, BSc Biological Sciences, Birmingham University. Experienced entrepreneur, innovator and business manager with extensive Life Science and Technology experience in the UK, European and US regulatory frameworks. Certified cricket nut.
Patrick is a seasoned Executive with a broad and diverse experience in Industrial Operation, Enterprise Integration and Global Alliances at GSK Vaccines. Most recently, as Head of Global Strategic Partnership, Patrick was in charge of several strategic alliances in Japan, China, Singapore and Brazil and is a Board member of three joint ventures; the Japan Vaccines Company, Qualivax and Tian Yuan. Previously he was the PMO leader for Novartis Vaccines GSK Integration (2014 - 2017) and a Board member and advisor for CEPI.
David is a Chartered Director and Fellow of the Institute of Directors and the RSA. He has held several executive and non-executive positions for international organisations, primarily in the Learning and Development, Higher Education and Assessment sectors. He is currently Chair of the Learning and Performance Institute International.
Simon joins Phenotypeca with over 20 years industry experience, having worked with some of the biggest biopharmaceutical manufacturing organisations in the world. After obtaining an engineering degree, Simon went on to become a management consultant with specific focus on the biopharmaceutical manufacturing supply chain area.
In 2002, Simon founded Biopharmaceutical Consulting and advised on a number of significant facility start up projects. In 2009 he was a founder of BioPhorum, a leading industry collaboration group, which has now become the most trusted environment for senior leaders from the biopharmaceutical industry to openly share and discuss emerging trends and challenges facing the industry. Simon also has strong skills as a facilitator and consultant, turning BioPhorum into a highly successful business, culminating in a private equity deal in 2018.
Marion holds over 29 years of experience in HR and training across private and public sectors and is the founder of renowned HR Consultancy Marion Parrish. As a specialist in supporting visionary companies through rapid growth and expansion, she will be focused on implementing management and HR practices that ensure commercial excellence and continue to make Phenotypeca a great place to work.
Acting Finance Director
As interim Financial Director, Matt will focus on helping Phenotypeca to streamline its financial data, reporting and processes, increase transparency and implement the latest technologies to support the business on this exciting journey. As a lover of the great outdoors, outside of work, Matt can be found spending time with his family and running around big open spaces.
Dr Anton Hutter
European & UK patent attorney
Anton is a European & UK patent attorney and partner in our Venner Shipley’s Chemical & Life Science team. He specialises in biotechnology and pharmaceuticals. In particular, he has a deep understanding of molecular biology, biochemistry & genetics, genomics & proteomics, immunology-related inventions, including therapeutic antibodies & immuno-oncology, bioinformatics, biomarkers & diagnostics, peptides & protein chemistry, vaccines, pharmaceuticals and SPCs.
Get In Touch
If you have any questions, or would like to find out more about our unique processes, please get in touch.
Phenotypeca Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF.